HyperMabs Inc.
$2,282,176.00 CAD
≈ 29 Canadians' average pay for a year
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- February 1, 2021 – May 31, 2023
- Reference
- nrc-cnrc:172-2020-2021-Q4-966019
Published purpose
FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing preclinical proof-of concept results showing antifibrotic efficacy and tolerability in relevant animal models. In addition, the project will allow HyperMabs to initiate critical manufacturing work that will support the preclinical studies a well as product characterization and release. This project represents important steps of the full non-clinical FB100 development program which will lead to clinical trials in early 2022.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported August 3, 2026 from open.canada.ca Grants & Contributions